search
Back to results

Role of Roflumilast in Ulcerative Colitis

Primary Purpose

Ulcerative Colitis

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Roflumilast 500 Ug ORAL TABLET [Daliresp]
corticosteroids +immune suppressive +amino salicylic acid
Sponsored by
Tanta University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ulcerative Colitis

Eligibility Criteria

15 Years - 80 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Patients referred to endoscopy units in Tanta University hospitals during the period of the study. Patient with mild to moderate UC diagnosed as: Clinical signs: Patients with moderate clinical disease have frequent loose, bloody stools (>4per day), mild anemia, and abdominal pain that is not severe. Patients have minimal signs of systemic toxicity, including a low-grade fever. Adequate nutrition is usually maintained, and weight loss. Endoscopy : are necessary to establish the chronicity of inflammation and to exclude other causes of colitis. Exclusion Criteria: Other inflammatory bowel disease (crohn's disease) . Patients <15 and >80 years Patients who didn't give consent to participate in the study Patients with contraindications of colonoscopy e.g. suspected colonic perforation, acute peritonitis, pregnancy, severe bleeding tendency, shock, uncooperative patient and if toxic mega colon is suspected were excluded History of allergic reaction to Roflumilast or any component of the formulation Like rash , hives ,itching and redness . Depression , thoughts of suicide , anxiety and emotional instability . Excessive weight loss . Moderate to severe hepatic impairment (child pugh class B or C) . Strong (CYP3A4) inducers : Barbiturates (phenobarbital) , Carbamazepine , Phenytoin , Rifampicin ( Risk , X interaction ) Loxapine ( Risk , X interaction )

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    conventional treatment group

    experimental treatment group

    Arm Description

    Group 1 (n=26): Patients will receive conventional treatment only of ulcerative colitis for 3 months.

    Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months

    Outcomes

    Primary Outcome Measures

    clinical improvement in ulcerative colitis severity
    To demonstrate the efficacy of Roflumilast and clinical improvement in (Mayo disease activity index) for assessment of ulcerative colitis severity

    Secondary Outcome Measures

    changes in serum levels of the measured biochemical parameters
    demonstrate changes in serum levels of the measured biochemical parameters Tumor necrosis factor-alpha (TNF-α) as pro inflammatory marker (ELISA). Signal transducer and activator of transcription 3 (STAT3) as a potential marker for apoptosis ( ELISA) Caspase-3 as a potential marker for apoptosis (ELISA).

    Full Information

    First Posted
    December 26, 2022
    Last Updated
    January 13, 2023
    Sponsor
    Tanta University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05684484
    Brief Title
    Role of Roflumilast in Ulcerative Colitis
    Official Title
    Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilast in Patients With Ulcerative Colitis.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    February 1, 2023 (Anticipated)
    Primary Completion Date
    February 2024 (Anticipated)
    Study Completion Date
    November 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Tanta University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This study aims to investigate possible efficacy and safety of Roflumilast in adult patients with ulcerative colitis disease .
    Detailed Description
    Study design and study population This study will be randomized, controlled, parallel study. It will be conducted on 52 patient having with mild to moderate degree ulcerative colitis disease divided into two groups Group 1 (n=26): Patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid) for 3 months. Group 2 (n=26): Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months Patient will be selected from Gastroenterology and Endoscopy Unit, Internal Medicine Department, Tanta University Hospital. A written informed consent will be obtained from all patients This study will be approved by the Research Ethics Committee of Tanta University. Any unexpected risks appeared during the course of research will be reported to the participants and ethical committee on time and documented through an adverse effects reporting form . Randomization will be carried out based on days of hospital admission

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Ulcerative Colitis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Model Description
    It will be conducted on 52 patient having with mild to moderate degree ulcerative colitis disease divided into two groups Group 1 (n=26): Patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid) for 3 months. Group 2 (n=26): Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    52 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    conventional treatment group
    Arm Type
    Active Comparator
    Arm Description
    Group 1 (n=26): Patients will receive conventional treatment only of ulcerative colitis for 3 months.
    Arm Title
    experimental treatment group
    Arm Type
    Experimental
    Arm Description
    Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months
    Intervention Type
    Drug
    Intervention Name(s)
    Roflumilast 500 Ug ORAL TABLET [Daliresp]
    Other Intervention Name(s)
    andomilast
    Intervention Description
    Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
    Intervention Type
    Drug
    Intervention Name(s)
    corticosteroids +immune suppressive +amino salicylic acid
    Intervention Description
    conventional treatment
    Primary Outcome Measure Information:
    Title
    clinical improvement in ulcerative colitis severity
    Description
    To demonstrate the efficacy of Roflumilast and clinical improvement in (Mayo disease activity index) for assessment of ulcerative colitis severity
    Time Frame
    3 months
    Secondary Outcome Measure Information:
    Title
    changes in serum levels of the measured biochemical parameters
    Description
    demonstrate changes in serum levels of the measured biochemical parameters Tumor necrosis factor-alpha (TNF-α) as pro inflammatory marker (ELISA). Signal transducer and activator of transcription 3 (STAT3) as a potential marker for apoptosis ( ELISA) Caspase-3 as a potential marker for apoptosis (ELISA).
    Time Frame
    7 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    15 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patients referred to endoscopy units in Tanta University hospitals during the period of the study. Patient with mild to moderate UC diagnosed as: Clinical signs: Patients with moderate clinical disease have frequent loose, bloody stools (>4per day), mild anemia, and abdominal pain that is not severe. Patients have minimal signs of systemic toxicity, including a low-grade fever. Adequate nutrition is usually maintained, and weight loss. Endoscopy : are necessary to establish the chronicity of inflammation and to exclude other causes of colitis. Exclusion Criteria: Other inflammatory bowel disease (crohn's disease) . Patients <15 and >80 years Patients who didn't give consent to participate in the study Patients with contraindications of colonoscopy e.g. suspected colonic perforation, acute peritonitis, pregnancy, severe bleeding tendency, shock, uncooperative patient and if toxic mega colon is suspected were excluded History of allergic reaction to Roflumilast or any component of the formulation Like rash , hives ,itching and redness . Depression , thoughts of suicide , anxiety and emotional instability . Excessive weight loss . Moderate to severe hepatic impairment (child pugh class B or C) . Strong (CYP3A4) inducers : Barbiturates (phenobarbital) , Carbamazepine , Phenytoin , Rifampicin ( Risk , X interaction ) Loxapine ( Risk , X interaction )
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    ahmed m. youness, master degree
    Phone
    0020114718892
    Email
    ahmedyounes881@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    sahar k. hegazy, master degree

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    25199861
    Citation
    Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014 Nov;89(11):1553-63. doi: 10.1016/j.mayocp.2014.07.002. Epub 2014 Sep 8.
    Results Reference
    background
    PubMed Identifier
    23317981
    Citation
    Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013 Feb;68(2):211.e1-33; quiz 244-6. doi: 10.1016/j.jaad.2012.10.036.
    Results Reference
    background
    PubMed Identifier
    31235952
    Citation
    Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019 Aug;20(8):970-979. doi: 10.1038/s41590-019-0415-0. Epub 2019 Jun 24.
    Results Reference
    background
    PubMed Identifier
    28831186
    Citation
    de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):739-749. doi: 10.1038/nrgastro.2017.110. Epub 2017 Aug 23.
    Results Reference
    background
    PubMed Identifier
    35514748
    Citation
    Elbadry M, Nour MO, Hussien M, Ghoneem EA, Medhat MA, Shehab H, Galal S, Eltabbakh M, El-Raey F, Negm M, Afify S, Abdelhamed W, Sherief A, Abdelaziz A, Abo Elkasem M, Mahrous A, Kamal G, Maher M, Abdel-Hameed O, Elbasuny A, El-Zayyadi I, Bassiony A, Moussa A, Bedewy E, Elfert A, El Kassas M. Clinico-Epidemiological Characteristics of Patients With Inflammatory Bowel Disease in Egypt: A Nationwide Multicenter Study. Front Med (Lausanne). 2022 Apr 19;9:867293. doi: 10.3389/fmed.2022.867293. eCollection 2022.
    Results Reference
    background
    PubMed Identifier
    30232010
    Citation
    Fujita Y, Khateb A, Li Y, Tinoco R, Zhang T, Bar-Yoseph H, Tam MA, Chowers Y, Sabo E, Gerassy-Vainberg S, Starosvetsky E, James B, Brown K, Shen-Orr SS, Bradley LM, Tessier PA, Ronai ZA. Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis. Cell Rep. 2018 Sep 18;24(12):3296-3311.e6. doi: 10.1016/j.celrep.2018.08.057.
    Results Reference
    background
    PubMed Identifier
    31127023
    Citation
    Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut. 2019 Sep;68(9):1688-1700. doi: 10.1136/gutjnl-2018-317977. Epub 2019 May 24.
    Results Reference
    background
    PubMed Identifier
    30272117
    Citation
    Trivedi PJ, Adams DH. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. J Crohns Colitis. 2018 Nov 28;12(12):1508. doi: 10.1093/ecco-jcc/jjy130. No abstract available.
    Results Reference
    background
    PubMed Identifier
    31099559
    Citation
    Zhang X, Dong G, Li H, Chen W, Li J, Feng C, Gu Z, Zhu F, Zhang R, Li M, Tang W, Liu H, Xu Y. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent. J Med Chem. 2019 Jun 13;62(11):5579-5593. doi: 10.1021/acs.jmedchem.9b00518. Epub 2019 May 31.
    Results Reference
    background
    PubMed Identifier
    27065076
    Citation
    Raker VK, Becker C, Steinbrink K. The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases. Front Immunol. 2016 Mar 31;7:123. doi: 10.3389/fimmu.2016.00123. eCollection 2016.
    Results Reference
    background
    PubMed Identifier
    32251674
    Citation
    Li H, Li J, Zhang X, Feng C, Fan C, Yang X, Zhang R, Zhu F, Zhou Y, Xu Y, Liu H, Tang W. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling. Biochem Pharmacol. 2020 Jul;177:113958. doi: 10.1016/j.bcp.2020.113958. Epub 2020 Apr 3.
    Results Reference
    background
    PubMed Identifier
    30883697
    Citation
    Li H, Fan C, Feng C, Wu Y, Lu H, He P, Yang X, Zhu F, Qi Q, Gao Y, Zuo J, Tang W. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity. Br J Pharmacol. 2019 Jul;176(13):2209-2226. doi: 10.1111/bph.14667. Epub 2019 May 17.
    Results Reference
    background
    PubMed Identifier
    29248522
    Citation
    Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S43-S52. doi: 10.1016/j.jaad.2017.11.056. Epub 2017 Dec 15.
    Results Reference
    background
    PubMed Identifier
    27732797
    Citation
    Kokkonen K, Kass DA. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases. Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:455-479. doi: 10.1146/annurev-pharmtox-010716-104756. Epub 2016 Oct 12.
    Results Reference
    background
    PubMed Identifier
    9171342
    Citation
    Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J. 1997 May 1;16(9):2271-81. doi: 10.1093/emboj/16.9.2271.
    Results Reference
    background
    PubMed Identifier
    30607971
    Citation
    Kosutova P, Mikolka P, Kolomaznik M, Balentova S, Adamkov M, Calkovska A, Mokra D. Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury. Physiol Res. 2018 Dec 31;67(Suppl 4):S645-S654. doi: 10.33549/physiolres.934047.
    Results Reference
    background

    Learn more about this trial

    Role of Roflumilast in Ulcerative Colitis

    We'll reach out to this number within 24 hrs